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Abstract
Cognitive impairments are considered core features in schizophrenia and other psychotic disorders. Cognitive
impairments are, to a lesser degree, also documented in healthy first-degree relatives. Although recent studies have
shown (negative) genetic correlations between schizophrenia and general cognitive ability, the association between
polygenic risk for schizophrenia and individual cognitive phenotypes remains unclear. We here investigated the
association between a polygenic score for schizophrenia (SCZPGS) and six well-defined cognitive domains, in addition
to a composite measure of cognitive ability and a measure of premorbid intellectual ability in 731 participants with a
psychotic disorder and 851 healthy controls. We also investigated the association between a PGS for general cognitive
ability (COGPGS) and the same cognitive domains in the same sample. We found no significant associations between
the SCZPGS and any cognitive phenotypes, in either patients with a psychotic disorder or healthy controls. For COGPGS
we observed stronger associations with cognitive phenotypes in healthy controls than in participants with psychotic
disorders. In healthy controls, the association between COGPGS (at the p value threshold of ≥0.01) and working
memory remained significant after Bonferroni correction (β= 0.12, p= 8.6 × 10−5). Altogether, the lack of associations
between SCZPGS and COGPGS with cognitive performance in participants with psychotic disorders suggests that either
environmental factors or unassessed genetic factors play a role in the development of cognitive impairments in
psychotic disorders. Working memory should be further studied as an important cognitive phenotype.
Introduction
Cognitive impairment is a core feature of schizophrenia
and other psychotic disorders1. Impairments are most
prominent in schizophrenia2–5, but also frequent in
bipolar disorders3,6–8. The genetic contribution to the risk
of developing a psychotic disorder is high, with heritability
estimates for schizophrenia and bipolar disorder ranging
from 0.6 to 0.89. Both disorders show high degrees of
polygenicity and have a considerable genetic overlap10.
The genetic contribution to cognitive abilities is also
substantial with a heritability estimate of 0.511. It is now
known that the phenotypic link between cognitive
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domains and a number of different psychiatric diagnoses
is at least partly explained common genetic variants12.
Mild cognitive impairments have been found in first-
degree relatives of probands with both schizophrenia and
bipolar disorder13,14, and a recent study estimated that as
much as one-third of the genetic risk for schizophrenia
could be mediated through cognition-relevant path-
ways15. Understanding the genetic underpinnings of
cognitive phenotypes in psychotic disorders could be key
in understanding the etiology of these disorders. The
considerable negative impact of cognitive impairment on
functional outcome and our current lack of efficient
treatment strategies emphasize the importance of identi-
fying the underlying mechanisms16,17.
The wealth of data uncovered by large-scale genome-
wide association studies (GWAS) offers promising
research opportunities for exploring the genetic archi-
tecture of psychotic disorders. The Psychiatric Geno-
mics Consortium (PGC) identified 108 separate genetic
loci statistically associated with schizophrenia risk after
correction for multiple testing, which accounted for
3.4% of the variation in liability to schizophrenia18.
These loci meet the high standard set for “true-positive”
hits, but applying more liberal p value thresholds (PTs)
reveals that the actual polygenic architecture of schi-
zophrenia comprises thousands of genetic variants, each
with very small effects that in aggregate explain a third
to a half of the heritability of the disorder18. This is the
basis for the calculation of polygenic scores (PGSs).
Here common allele associations from a GWAS dis-
covery sample are used to calculate an aggregate PGS as
the cumulative effect sizes that differ between cases and
controls. PGSs can be created for any investigated
phenotype and can be used to explore the associations
between the polygenic basis of this phenotype and other
individual characteristics.
How the PGS for schizophrenia (PGSSCZ) is related to
cognition has been studied in both clinical samples and in
the general population. Results from studies of clinical
samples have been mixed: While one study found strong
negative associations between PGSSCZ and seven cognitive
domains19, other studies have reported a lack of sig-
nificant associations20–23. Two studies have in addition
found PGSSCZ to be negatively associated with general
cognitive ability in healthy controls but not in
patients24,25. A plausible explanation for the latter find-
ings is that the effect of the association between PGSSCZ
and cognition is overshadowed by non-genetic illness
factors in patients, creating stronger associations between
genetic and cognitive measures in the healthy control
group than in the patient group. In line with this, one of
these studies25 found that higher PGS for intelligence was
associated with better general cognitive ability in both
patients and healthy controls, but with a stronger effect in
healthy controls. However, the study did not explore the
effect on specific cognitive domains.
As there is no consensus on the operationalization of
cognitive domains, studies vary in their selection of cog-
nitive tests. In genetic studies, general cognitive ability is
frequently operationalized as a composite score of avail-
able tests referred to as Spearman’s g, a term for the latent
variable thought to underlie all cognitive domains26.
Because g is confirmed as a valid construct26,27 with high
heritability26,28, and allows for the combination of unre-
lated cognitive tests to increase sample size and statistical
power, its frequent use in genetic studies is unsurprising.
However, substantial and independent genetic effects on
specific cognitive domains have also been demonstrated27.
The variation in both sample sizes and cognitive pheno-
types used in studies of PGSSCZ makes interpretation of
results challenging29, and at present only one study has
investigated how the PGSSCZ is associated with a broader
selection of cognitive phenotypes known to be influenced
by psychosis in both individuals with psychosis and
healthy controls19.
In summary: While a genetic basis for cognitive
impairment in psychotic disorders appears estab-
lished15,30,31, the nature of this association is complex and
its true extent remains unclear. Twin studies indicate that
the shared genetic basis for schizophrenia and cognition is
substantial32,33. However, a population-based twin study
with measures of premorbid cognitive ability found only
7% shared genetic variance between psychosis and cog-
nition34. In addition, while the association between g and
cognitive domains are considerable, they are not identical
and probably have different genetic architectures with
different associations to the genetic basis of psychotic
disorders35.
To increase our understanding of the genetic relation-
ship between psychotic disorders and cognitive function,
we here investigated the association between PGSSCZ and
a well-defined set of cognitive domains in a large sample
of participants with a psychotic disorder and healthy
controls. In addition, we explored the associations
between the PGSs for general cognition (PGSCOG) based
on a GWAS with stringent inclusion criteria, and the
same set of cognitive domains in the same group of par-
ticipants. Our hypothesis was that we would find negative
associations between the PGSSCZ and cognitive domain
scores and positive associations between and PGSCOG and
cognitive domain scores in both groups, but that the effect
size of the associations would be higher in healthy con-
trols. We also included an estimate of premorbid intelli-
gence, and hypothesized less differences between
participants with psychosis and healthy controls for this
measure.
Engen et al. Translational Psychiatry          (2020) 10:416 Page 2 of 9
Methods
Participants, clinical measures, and study design
The current study was based on the inclusion criteria
for the thematically organized psychosis study. All
recruited participants were between 18 and 65 years. For
the research questions in the current study, we included
participants with declared European ancestry who had
participated in cognitive assessment and met the criteria
for a psychotic disorder. Psychotic bipolar disorder was
included based on genetic overlap with schizophrenia and
the phenotypic similarity with regards to cognitive
impairment. The sample included participants with schi-
zophrenia spectrum disorders (N= 522) (schizophrenia
n= 294, schizophreniform disorder n= 28, schizoaffec-
tive disorder n= 72, and psychosis not otherwise specified
n= 128) and psychotic bipolar spectrum disorders (n=
209) (bipolar I disorder n= 170, bipolar II disorder n=
28, bipolar disorder not otherwise specified n= 11),
resulting in a clinical sample of 731 psychosis spectrum
participants. Clinical interviews for DSM-IV (Diagnostic
and Statistical Manual of Mental Disorders, fourth edi-
tion) diagnoses in patients36 were performed by psychol-
ogists, psychiatrists, or medical doctors. Healthy controls
(n= 851) were randomly selected from the population
registry in the same catchment area. The healthy controls
were screened with the Primary Care Evaluation of
Mental Disorders (PRIME-MD)37 and a family history
interview, performed by individuals with a master’s degree
in psychology or neuroscience. Controls were not inclu-
ded if they had a personal or family (first-degree) history
of a psychotic disorder. Both psychosis spectrum partici-
pants and healthy controls were excluded if they did not
speak a Scandinavian language, had a history of serious
head injury, suffered from a known medical or neurolo-
gical condition interfering with brain functioning, or
intelligence quotient < 70. Demographic and clinical
characteristics are presented in Table 1.
The Positive and Negative Syndrome Scale38 Wall-
work’s five factor model39 was used to measure symp-
toms. The Alcohol Use Disorder Identification Test and
the Drug Use Disorder Identification Test40 were used to
assess alcohol use and drug use, respectively. Duration of
illness was based on information from the severe com-
bined immunodeficiency interview, and was calculated as
the time in years from the first episode of psychosis or
mania. Use of antipsychotic medication was recoded into
defined daily dosages41.
All participants in the cognitive assessments were
included to increase statistical power. However, some
participants were lacking scores for one or more subtests,
precluding the calculation of a cognitive composite score
for these individuals. Therefore, the sample varies from
n= 726 for verbal learning to n= 533 for the cognitive
composite score. Mean scores and Ns for participants
with psychosis and healthy controls for all tests and
domains are presented in Table 2. Written informed
consent was obtained from all participants.
Genetic analyses
DNA samples obtained from blood or saliva were sent
for genotyping in six separate batches between the years
of 2014 and 2017 at deCODE Genetics (Reykjavik, Ice-
land). The samples were analyzed using Illumina Human
OmniExpress12 (first four batches), Infinium OmniEx-
press24 (fifth batch), and Illumina Global Screening Array
(sixth batch) platforms, respectively. Identical but inde-
pendent procedures were followed for sample batches
genotyped on different platforms. PLINK version 1.942
was deployed to perform the necessary pre-imputation
quality control. This involved removal of any samples
with possible contamination (heterozygosity more than
five standard deviations above the mean) or too low
coverage ((<80%) to enable its detection) and any variants
with genotyping rate lower than 95%, Hardy–Weinberg
disequilibrium test p value lower than 10−4, and high rate
of Mendel errors (https://www.cog-genomics.org/plink/
1.9/basic_stats#Mendel) in eventual trios or significant
(false discovery rate < 0.5) batch effects (in case multiple
batches were being processed simultaneously). The
quality-controlled genotypes were phased using Eagle43,
and missing variants were imputed with MaCH44,45 using
version 1.1 of the trans-ethnic reference sample put
together by the haplotype reference consortium (HRC)46.
High-quality variant sets from the quality control proce-
dure (see Supplementary information) were selected to
impute each individual’s sex and compute each indivi-
dual’s genetic principal components (PCs). The latter
consisted of the individual’s components along the 20 first
eigenvectors of the pairwise genetic covariance matrix of a
sub-sample of unrelated individuals from the reference
(HRC) panel. Following the quality control and





N Total (% females) 851 (47) 731 (48)
Mean age (SD) 32.7 (9.0) 31.3 (10.8)
Education years (SD) 14.4 (2.2) 12.8 (2.6)
AP medicationa (SD) 1.0 (0.7)
Duration of illnessb (SD) 6.3 (7.4)
SD standard deviation, AP antipsychotic.
aDaily antipsychotic dosage relative to the average recommended daily dosage.
One hundred and seventy-five individuals with missing data.
bYears from first episode with psychosis or mania. Twenty-seven individuals with
missing data.
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imputation procedure, variants with information score
<0.8 or minor allele frequency <0.01 were removed. In
addition, individual genotypes imputed with <75% con-
fidence were set to missing, and the remaining ones were
converted to best guess hard allelic dosages. Finally,
individuals with imputation rate <95% and an up to third-
degree relative with better imputation rate or differing
annotated and imputed sex were excluded. For more
detailed descriptions of the quality control and imputa-
tion procedures, refer to the Supplementary information.
Polygenic scores
The SCZPGS were computed following the method
described by Purcell et al.47. A meta-analysis covering all
PGC sub-studies, except our sample, was performed to
obtain risk allele effect sizes [ln(OR)] for all imputed
variants. We then used PRSice48 to compute PGSs based
on seven increasing PTs: PT ≤ 5 × 10−8, PT ≤ 1 × 10−5,
0.001, 0.01, 0.05, 0.1, and 0.5. The SCZ discovery sample
used for SCZPGS is based on 36,989 participants with
schizophrenia and 113,079 healthy controls. Participants
Table 2 Cognitive assessment scores.
Psychosis Controls
N Mean ± SD N Mean ± SD
Cognitive domain
Verbal learning 726 −0.75 ± 1.27 850 0.00 ± 1.00
CVLT-II verbal learninga 537 50.18 ± 11.79 380 57.14 ± 9.73
HVLT verbal learningb 189 24.87 ± 5.58 472 28.23 ± 3.94
Verbal memory 685 −0.69 ± 1.31 850 0.00 ± 1.00
CVLT-II delayed free recalla 535 11.42 ± 3.37 380 13.21 ± 2.69
HVLT delayed free recallb 150 8.85 ± 2.60 472 10.20 ± 1.73
Processing speed 679 −0.96 ± 1.13 845 0.00 ± 0.78
WAIS digit-symbol codinga 536 62.03 ± 15.56 380 77.46 ± 13.23
BACS digit-symbol codingb 189 47.43 ± 10.90 472 58.31 ± 9.15
D-KEFS color naming*d 682 33.23 ± 7.16 847 28.16 ± 4.64
D-KEFS word reading*d 682 23.56 ± 5.02 846 21.25 ± 3.71
Executive functions
Working memory 564 −0.60 ± 0.88 812 0.00 ± 0.88
WAIS letter-number sequencinga 461 9.47 ± 2.38 366 11.51 ± 2.56
MCCB letter-number sequencingb 184 13.58 ± 3.17 472 15.17 ± 3.03
WAIS digit spand 642 14.74 ± 3.64 827 16.44 ± 3.71
Attentional control 678 −0.92 ± 1.47 824 0.00 ± 0.86
D-KEFS inhibition*,d 682 59.00 ± 16.51 845 48.55 ± 9.79
D-KEFS inhibition-switching*,d 678 64.26 ± 17.76 825 55.13 ± 11.67
Category fluency 693 −1.06 ± 1.20 850 0.00 ± 0.99
D-KEFS category fluencya 505 40.58 ± 9.65 381 49.25 ± 7.85
MCCB category fluencyb 188 23.03 ± 6.44 470 28.46 ± 5.87
General cognitive ability
NARTc,d 635 −0.47 ± 1.19 825 0.00 ± 1.00
Cognitive composite score 533 −0.81 ± 0.89 802 0.00 ± 0.61
All domains in bold are transformed into z-scores using the healthy control mean and standard deviation. The cognitive composite score is averaged over all domains
except NART, which is an estimate of premorbid intellectual functioning.
*Scores reversed when transformed into z-scores to make higher values reflect better performance.
aTest from Battery 1.
bTest from Battery 2.
cTest included in both assessment batteries.
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come from a total of 49 case–control samples (46 Eur-
opean and 3 East Asian) and 3 family-based samples of
European ancestry18.
The PGSCOG were computed following the same pro-
cedure for seven increasing PTs: PT ≤ 5 ×10−8, PT ≤ 1 ×
10−5, 0.001, 0.01, 0.05, 0.1, and 0.5, but using a meta-
analysis of COGENT consortium sub-studies of general
cognitive function49. This discovery sample consists of
35,298 individuals with European ancestry from 24 stu-
dies (mean age of 45.6 (SD ± 8.6) 51.4% females). Most of
these studies are of clinical populations (schizophrenia,
Alzheimer’s disease, cardiovascular disorders), but the
healthy controls and participants in studies of the general
population were also included.
Measures of cognition
All participants were assessed with a comprehensive
cognitive assessment battery. At the start of the study,
there was no international consensus regarding which
tests to use and the study constructed a battery based on
the knowledge about cognitive domains that were most
affected by psychotic disorders (“battery 1”). With the
development of the Measurement and Treatment
Research to Improve Cognition in Schizophrenia
(MATRICS) Consensus Cognitive Battery (MCCB)50, the
study decided to change to the MCCB (“battery 2”). Since
both batteries focused on domains affected by psychotic
disorders, they covered essentially the same areas, but
used somewhat different specific tests. For the purpose of
the study results from the two batteries were merged
according to the following procedure51: Cognitive test
scores were first converted into z-scores based on the
mean scores and standard SDs of the healthy control
group. Tests were combined into the six specific cognitive
domains based on their well-recognized relevance to
cognitive impairment in psychotic disorders52, and
included Attentional control, Category fluency, and
Working memory (these three covering different aspects
of Executive function) together with Processing speed,
Verbal learning, and Verbal memory.
Attentional control comprised the inhibition and the
inhibition/switching conditions of the Delis-Kaplan
Executive Functions System (D-KEFS) Color-Word
Interference task53; Category fluency was constructed
merging the Category fluency test from D-KEFS53 and the
Category fluency test from the MCCB50.
Processing speed was measured using the word reading
and color naming conditions of the Color-Word Inter-
ference task from the D-KEFS53. In addition, the digit
symbol tests from WAIS-III54 and BACS50,55 were inclu-
ded.Working memory consisted of the WAIS-III digit span,
forward and backward, and the WAIS-III Letter-Number
Sequencing test, merged with Letter-Number Span from
the MCCB50. The Verbal learning and Verbal memory
domains were constructed merging relevant conditions
from the California Verbal Learning Test II and the Hop-
kins Verbal Learning Test-Revised, respectively50,56.
In addition to investigating these six domains sepa-
rately, we also combined them into a Cognitive composite
score as a measure of general cognitive ability. The cog-
nitive composite score was constructed as the individual’s
mean z-score across the six domains. Finally, the National
Adult Reading Test (NART)57 was included as an estimate
of premorbid intelligence. The Norwegian NART is a
valid measure of premorbid intelligence58.
Statistical analyses
We used SPSS version 25 for the analyses of the main
research question. Means are reported for data with
normal distribution and all test are two-tailed with α set
to p < 0.05. We started the analyses by selecting the
relevant ancestry PCs to be included in the analyses, by
bivariate association analyses between the 20 first ancestry
PCs, and the ten PGSSCZ PT levels and case–control sta-
tus, resulting in a list of 16 PCs that were associated at the
p ≤ 0.05 level with any of these. The next step was to run
ten separate logistic regressions (one for each PT) with
case–control status as the dependent variable correcting
for genotyping batch and the 16 PCs to identify the PT
with the highest explained variance in case–control status.
The PT with the best fit based on the Akaike information
criterion was PT ≤ 0.01 (Fig. 1). PT ≤ 0.01 was thus selected
for testing for associations between PGSSCZ and the
cognitive phenotypes in the subsequent analyses. For the
PGSCOG, all available PT levels were used in the main
analyses.
The main analyses to investigate the association
between PGSSCZ PT ≤ 0.01 and cognitive domains were
multiple linear regression analyses, with the different
cognitive phenotypes as dependent variables and the
PGSSCZ as the independent variable introduced at the last
step of the analysis after, controlling for age, sex, geno-
typing batch, and PCs. For this step, we selected PCs that
had a bivariate association at the p ≤ 0.05 level to either
the PGSSCZ PT ≤ 0.01, the seven PGSCOG PT levels or to
any of the eight cognitive phenotypes, resulting in nine
PCs. For the next research question, the multiple linear
regression analyses were repeated, this time with the
seven PGSCOG PT levels as independents. All these ana-
lyses were done separately for psychosis participants and
for healthy controls. The α level was set at 0.05 for all
tests, with Bonferroni corrections. We adjusted for testing
in two different populations for eight domains and one
PGSSCZ PT, yielding a corrected threshold of p < 0.003 (16
tests) for PGSSCZ and likewise yielding a corrected
threshold of p < 0.00045 (112 tests) for the seven PGSCOG
PT levels. The difference in regression coefficients
between cases and controls were tested using the method
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of Weaver and Wuensch, taking the sample size, the
number of independent variables, and the standard error
into account59. In the follow-up analyses, all regressions
were repeated with only participants within the schizo-
phrenia spectrum.
Results
The PGSSCZ predicted case–control status but was not
significantly associated with any cognitive domain
The associations between the PGSSCZ at PT ≤ 0.01 and
the cognitive phenotypes are displayed in Fig. 1. Except
for a nominally significant association to verbal learning
for individuals with psychosis (β=−0.11, p= 0.03), there
were no significant associations between the PGSSCZ and
the remaining cognitive phenotypes (numerical values for
βs, 95% confidence intervals (CIs), and p values for both
participants with psychosis and healthy controls are pre-
sented in Supplementary Table S1). Repeating the ana-
lyses, including only participants within the schizophrenia
spectrum, did not change the results.
The PGSCOG predicted working memory performance in
controls
The analyses were repeated using the seven pre-selected
PGSCOG PT levels to evaluate how the genetic basis for
general cognition was associated with the cognitive phe-
notypes. There were no associations between PGSCOG and
cognitive phenotypes that reached unadjusted levels of
statistical significance across the seven PTs in participants
with a psychotic disorder. In healthy controls, we
observed the strongest associations between PGSCOG and
cognitive phenotypes at PT ≤ 0.01, where nominally sig-
nificant results were for the cognitive composite score
(β= 0.06, p= 0.01), NART (β= 0.08, p= 0.02), and
working memory (β= 0.12, p= 0.00009). Only the asso-
ciation with working memory reached the Bonferroni-
corrected level of significance. The adjusted R2 for this
model was 0.022 and the change in adjusted R2 when
entering the PGSCOG at the last step was 0.017. The
association between cognitive phenotypes and PGSCOG at
PT ≤ 0.01 are displayed for both psychosis participants and
healthy controls in Fig. 1. (The numerical values for βs,
95% CIs, and p values for both psychosis participants and
healthy controls at all PTs are presented as Supplementary
material (Supplementary Table S2), while Supplementary
Fig. S1 graphically shows the association at the six
remaining PT levels analyzed). Repeating the analyses
including only patients within the schizophrenia spectrum
did not change the results. The nominal p value for the
difference in regression coefficients between patients and
controls for the analysis of working memory and PGSCOG
at PT ≤ 0.01 was 0.05, below the level of statistical sig-
nificance after correction for multiple testing.
Symptoms and substance use did not moderate the
association between PGSCOG and cognitive phenotypes in
the psychosis sample
The analysis that yielded the strongest associations
between the PGSCOG and cognitive phenotypes in healthy
controls at PT ≤ 0.01 (working memory) were repeated in
participants with a psychotic disorder, controlling for
clinical characteristics that potentially could influence the
associations (illness history, symptom and substance use
scores, and antipsychotic medication use). Clinical vari-
ables with associations p < 0.1 to the cognitive phenotypes
(Supplementary Table S3) were entered in the analysis.
Fig. 1 The left and right figures present PGSCOG and PGSSCZ associations with the eight cognitive phenotypes at PT level= 0.01,
respectively. The axes denote the associations (β) to healthy controls (x) and individuals with psychosis (y). The size and shape of the bubbles on
both plots represent the significance of the association.
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This did not significantly alter the associations between
PGSCOG and the cognitive phenotypes in the psychosis
group. (The analysis for working memory and PGSCOG at
PT ≤ 0.01 is shown in Supplementary Table S4.) Repeating
the analyses including only patients within the schizo-
phrenia spectrum did not affect the results.
Discussion
The current study is the largest to date investigating the
association between a broad and well-defined set of cog-
nitive domains and PGSSCZ and PGSCOG, in both healthy
controls and participants with psychotic disorders.
Overall, we did not find the hypothesized negative asso-
ciations between PGSSCZ and cognitive phenotypes.
However, we did observe a statistically (Bonferroni-cor-
rected) significant association between PGSCOG at PT ≤
0.01and working memory in healthy controls. This asso-
ciation in healthy controls was nominally stronger than in
participants with psychotic disorders (p= 0.05).
A previous study, in a slightly smaller sample than the
current, investigated the association between PGSSCZ and
estimates of premorbid and current cognitive abilities in
patients with psychosis and healthy controls24. They found
that premorbid intelligence was not associated with
PGSSCZ, whereas better general cognitive ability was asso-
ciated with lower PGSSCZ in healthy controls. The negative
finding for premorbid cognitive abilities was replicated in a
large population-based study. The authors interpreted this
to suggest that tests used to measure current cognitive
abilities are more directly linked to the genetic risk factors
of schizophrenia. In the present study, we also found that
both measures of premorbid (NART) and current (com-
posite score) cognitive abilities were not associated with
PGSSCZ at all (and only nominally associated with the
PGSCOG in healthy controls). While some findings could be
based on low statistical power, our study supports the
notion that cognitive phenotypes differ in their associations
with the genetic basis of schizophrenia.
Several previous studies have, however, found significant
associations between PGSSCZ and cognitive phenotypes,
while others have not20,22,23,60. In a recent review of PGSSCZ
and cognitive functioning, the authors hypothesize that
studies using improved cognitive phenotypes, such as the
MCCB, will detect associations29. In line with this, a recent
study including 127 patients and 136 healthy controls found
significant associations between PGSSCZ and all domains of
the MCCB, including the cognitive composite score19. The
present study investigated several tests from the MCCB in a
significantly larger sample. This suggests that refining the
cognitive phenotypes alone will not increase the power to
detect associations. Since our sample size is larger than most
of the previous studies reporting significant associations, our
lack of findings is also not primarily based on lack of sta-
tistical power relative to these studies.
Recent studies indicate a complex pattern of association
between the genetic basis for cognition and schizophrenia:
While most (but not all) schizophrenia risk alleles were
associated with lower intelligence, around half of bipolar
disorder risk alleles were associated with higher intelli-
gence61. Further, among the 75 loci shared between
bipolar disorder and intelligence, there was an equal dis-
tribution of agonistic and antagonistic effect directions
possibly explaining the overall non-significant correlation
between these two phenotypes61. Another GWAS analysis
reports a similar complex genetic relationship between
schizophrenia and cognitive measures35. In line with this,
other studies have found weak—and in some cases posi-
tive—associations between educational attainment as a
proxy for cognitive abilities and schizophrenia62, despite
behavioral data showing a strong negative association
between schizophrenia and attaining higher education.
Another study suggests that this may be caused by a
positive association between educational attainment and
risk alleles shared between schizophrenia and bipolar
disorder, suppressing the negative association with risk
alleles unique to schizophrenia63. Taken together, the
findings indicate a highly complex and not uniformly
negative association between schizophrenia risk variants
and cognitive functioning that may explain the lack of
association between PGSSCZ and cognitive abilities.
Underpowered GWAS discovery samples or impreci-
sion in current methods used to generate PGSSCZ could
account for lack of clear answers. The construction of the
PGSSCZ is powered by design to explain variance in
case–control status and the phenotypic variance
explained by the currently available PGSSCZ is relatively
low64. Here, increased sample sizes in the GWAS on
which the PGS is based may generate PGSs with better
predictive power and as the statistical power of GWASs
increase, the improved PGS is may become a better tool
for future personalized medicine65. As of now, any asso-
ciations (or lack thereof) between PGSs and complex
phenotypes should be interpreted with caution.
The finding regarding working memory is noteworthy.
Working memory may be a particularly important
domain because it has been suggested that it is at the core
of the widespread deficits observed across psychotic dis-
orders through its influence of proactive control66.
According to theory, the inability to retain and organize
information in short-term memory impairs the ability to
proactively guide thoughts and behavior in an efficient
manner and leads to observed impairments in several
domains. A recent study of patients with psychotic dis-
orders found significant associations between PGS for
educational attainment and measures of working mem-
ory60; however, with a relatively limited influence on the
explained variance. The diagnostic composition, sample
size, and cognitive measures were approximately the same
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as the current. Educational attainment is perceived as a
less precise proxy or indication of cognitive abilities; the
larger sample size of educational attainment GWASs
could, however, lead to a better calculation of the edu-
cational attainment PGS. The study does not report
directly on findings in their somewhat smaller healthy
control sample. Taken together, our results support the
notion that clinical and environmental factors in persons
with a psychotic disorder could explain more variance in
cognitive phenotypes than in healthy controls, and that
current estimates may overstate the role of cognition as a
part of the genetic etiology of psychotic disorders. Future
studies should include a focus on working memory.
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